New hope for tough ovarian cancers: experimental drug ABBV-901 enters human testing

NCT ID NCT07278336

First seen Jan 05, 2026 · Last updated May 10, 2026 · Updated 22 times

Summary

This early-phase study tests an investigational drug called ABBV-901, given alone or with a standard drug (bevacizumab), in about 207 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if tumors shrink. Participants receive the drug through an IV and will have regular blood tests and scans over about 3 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hadassah Medical Center-Hebrew University /ID# 278420

    RECRUITING

    Jerusalem, 91120, Israel

  • NEXT Oncology - San Antonio /ID# 278606

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Next Virginia /ID# 278607

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Rambam Health Care Campus /ID# 278418

    RECRUITING

    Haifa, 3109601, Israel

  • Saitama Medical University International Medical Center /ID# 278437

    RECRUITING

    Hidaka, Saitama, 350-1298, Japan

  • Shizuoka Cancer Center /ID# 278538

    RECRUITING

    Sunto-gun, Shizuoka, 411-8777, Japan

  • Start Mountain Region /ID# 278609

    RECRUITING

    West Valley City, Utah, 84119, United States

  • The Chaim Sheba Medical Center /ID# 278416

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

Conditions

Explore the condition pages connected to this study.